Common Sense for the Biochemist

This is the first of two stories today taken from Plantpharma.org. Chlorogen today firmed up its expression platform utilizing expression of recombinant proteins in the plant chloroplast. In this story found on Plantpharma.org, the company stated that it has acquired a license to CTT (Chloroplast transformation technology) patents held by Rutgers university. Not much to this story, but it looks like I could do a little research to find out how these patents match up with what Chlorogen already has. From the sounds of the press release, it looks like this will prevent Chlorogen from having to dance around some potential patent issues with CTT and will probably give them some more room to develop their technology. Clearing up patent issues without the use of vultures - I mean - lawyers is always a good thing in my book. Chlorogen is also in the middle of raising about $6 million in capital which should be closing in October. Looks like it may be a busy winter for these guys.